The effect of Zinc on Hyperbilirubinemia of newborns

The effect of Zinc on Hyperbilirubinemia of healthy and normal newborns, a clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061515835N5

Enrollment

112

Registered

2017-10-14

Start date

2017-11-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal physiological jaundice. Neonatal jaundice, unspecified

Interventions

Intervention 1: Daily administration of 5 mg (2.5 ml) twice daily of 10 mg per 5 ml Zinc Sulfate syrup produced by Donya-ye-Behdasht company in case group until the newborn is admitted. Intervention 2

Eligibility

Sex/Gender

All

Age

3 Days to 7 Days

Inclusion criteria

Inclusion criteria: Term infants Breast-feeding Jaundice Photo-therapy Serum bilirubin 15-20 mg/dL Age 3 to 7 days Using no other drug

Exclusion criteria

Exclusion criteria: Recent weight loss Infection Hemolytic disease Oral intolerance Congenital birth defects Gastrointestinal anomalies Parental dissatisfaction for participation in the study Need for ventilators Need for blood transfusion

Design outcomes

Primary

Measure	Time frame
Serum total bilirubin in hospitalization days. Timepoint: One time measuring before prescribing of Zink and immediately after that daily measurment in three days. Method of measurement: Colorimetric method by Lathe and Ruthven.;Hospitalization days. Timepoint: Patient's discharging day. Method of measurement: Computation the number of hospitalization days from admission to discharge.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Parisa Khoshnevis Asl

Zanjan University of Medical Sciences

khoshnevis@zums.ac.ir+98 243313328

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026